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Cleasby ME, Jarmin S, Eilers W, Elashry M, Andersen DK, Dickson
G, Foster K. Local overexpression of the myostatin propeptide increases
glucose transporter expression and enhances skeletal muscle glucose dis-
posal. Am J Physiol Endocrinol Metab 306: E814–E823, 2014. First pub-
lished January 28, 2014; doi:10.1152/ajpendo.00586.2013.—Insulin resis-
tance (IR) in skeletal muscle is a prerequisite for type 2 diabetes and
is often associated with obesity. IR also develops alongside muscle
atrophy in older individuals in sarcopenic obesity. The molecular
defects that underpin this syndrome are not well characterized, and
there is no licensed treatment. Deletion of the transforming growth
factor- family member myostatin, or sequestration of the active
peptide by overexpression of the myostatin propeptide/latency-asso-
ciated peptide (ProMyo) results in both muscle hypertrophy and
reduced obesity and IR. We aimed to establish whether local myo-
statin inhibition would have a paracrine/autocrine effect to enhance
glucose disposal beyond that simply generated by increased muscle
mass, and the mechanisms involved. We directly injected adeno-
associated virus expressing ProMyo in right tibialis cranialis/extensor
digitorum longus muscles of rats and saline in left muscles and
compared the effects after 17 days. Both test muscles were increased
in size (by 7 and 11%) and showed increased radiolabeled 2-deoxy-
glucose uptake (26 and 47%) and glycogen storage (28 and 41%) per
unit mass during an intraperitoneal glucose tolerance test. This was
likely mediated through increased membrane protein levels of GLUT1
(19% higher) and GLUT4 (63% higher). Interestingly, phosphoryla-
tion of phosphoinositol 3-kinase signaling intermediates and AMP-
activated kinase was slightly decreased, possibly because of reduced
expression of insulin-like growth factor-I in these muscles. Thus,
myostatin inhibition has direct effects to enhance glucose disposal in
muscle beyond that expected of hypertrophy alone, and this approach
may offer potential for the therapy of IR syndromes.
hypertrophy; insulin sensitivity; glucose transporters; insulin-like
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INSULIN RESISTANCE (IR) in skeletal muscle is an essential
precursor for the development of type 2 diabetes (T2D) in
humans, since this tissue is responsible for a large proportion
of postprandial glucose disposal. IR is frequently associated
with both increasing adiposity and age, but also commonly
coexists with age-associated loss of muscle mass (sarcopenia)
in a syndrome referred to as “sarcopenic obesity.” This syn-
drome is a substantial cause of morbidity and mortality in the
elderly (affecting 4–12% of the elderly population) (37, 47),
both as a consequence of metabolic derangement but also
because of frailty-related accidents and immobility. However,
no licensed medications exist that are effective for sarcopenia
or sarcopenic obesity; thus, it is imperative that a greater
understanding is gained of the mechanisms involved in its
development, such that potential therapeutic targets can be
identified.
Myostatin is a member of the transforming growth factor-
(TGF-) family of secreted proteins that is almost exclusively
expressed by skeletal muscle, and this tissue is also its princi-
pal target, where it inhibits myocyte hypertrophy (24, 27).
Naturally occurring mutations of myostatin have been identi-
fied in a number of species, resulting in a “double muscling”
phenotype (24). Similarly, myostatin null mice and mice
administered with short-hairpin RNAs targeting myostatin
show markedly increased muscle mass, although postnatal
myostatin inhibition results in hypertrophy only, whereas
null mice demonstrate both hypertrophy and hyperplasia
(30, 33). Myostatin achieves its effects through activation of
the Mothers against decapentaplegic homologs (25) and
phosphoinositol 3-kinase (PI3K)/protein kinase B (Akt)
pathways (3, 56), the latter being the site for cross talk with
prohypertrophic insulin-like growth factor-I (IGF-I) signal-
ing in muscle (56). However, activation of the PI3K/Akt
pathway also plays an important role in insulin-stimulated
glucose disposal in skeletal muscle (11, 53), and this is
defective in muscle IR (9). In addition, myostatin modulates
activation of AMP-activated protein kinase (AMPK) in
muscle (59), the key enzyme in a second pathway that plays
a role in both muscle metabolism and growth (26, 29).
As might be predicted, therefore, myostatin null and mutant
mice also resist diet-induced obesity and IR (17, 34, 54, 59),
while conversely administration of myostatin to mice causes IR
(19). In addition, myostatin mRNA is increased in muscle from
ob/ob and high-fat diet-fed mice (2) and obese (35, 40) and
diabetic (39) humans, but, significantly, this change is not
reflected in altered plasma levels in the latter group (6). Thus,
it is as yet unclear whether myostatin’s beneficial effects on
metabolism are due purely to an increase in muscle mass that
increases the capacity for insulin-stimulated glucose disposal,
through an effect on muscle metabolism that is additional to
this, or indeed whether the main beneficial effects are exerted
primarily in other tissues. However, it is clear that myostatin
represents a key potential molecular mediator of the pathogen-
esis of IR and sarcopenic syndromes, including sarcopenic
obesity.
Active myostatin is generated by cleavage of a precursor
protein and subsequent dimerization. The myostatin propep-
tide, containing the NH2-terminal latency-associated peptide
(ProMyo) only, sequesters the myostatin dimer and prevents its
binding to the activin IIB receptor (ActRIIB) (28). Mice
overexpressing the propeptide show both increased muscle
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fiber size and number (28) and resistance to diet-induced
obesity (60), whereas we have previously shown that intrave-
nous administration of adeno-associated virus (AAV)-8-myo-
statin propeptide (ProMyoAAV) leads to a generalized dose-
dependent increase in muscle mass (12, 32). However, studies
using whole body genetic manipulations are unable to delineate
the importance of the autocrine/paracrine effects of myostatin
on insulin sensitivity in vivo. In this study we overexpressed
ProMyo in a single muscle group to establish whether this
would be sufficient to enhance insulin-stimulated glucose dis-
posal in a tissue-autonomous fashion and whether any increase
would be proportional to the enhanced muscle mass, or be the
result of an additional effect of myostatin inhibition on muscle
signaling or metabolism.
MATERIALS AND METHODS
Materials. General reagents were supplied by Sigma-Aldrich
(Gillingham, Dorset, UK). pY608-insulin receptor substrate (IRS) 1
antibody was from Biosource International (Camarillo, CA), total
IRS1, total glycogen synthase kinase (GSK) 3/, and GLUT1
antibodies from Millipore (Billerica, MA), caveolin-1 antibody from
Santa Cruz Biotechnology (Santa Cruz, CA), actin and desmin anti-
bodies from Sigma, and all others from Cell Signaling Technology
(Beverly, MA).
Preparation of viral vector. The ProMyoAAV used was as previ-
ously described (12). The murine propeptide sequence used shows
99% homology with that of rat, whereas the mature peptide shares
100% homology in its amino acid sequence. HEK293T cells were
cultured in roller bottles in Dulbecco’s modified Eagle’s medium,
supplemented with 10% (vol/vol) fetal bovine serum and incubated at
37°C, 5% CO2. Recombinant pseudotyped AAV2/8 vector stocks
were generated by using polyethylenimine and transfection with the
pDD345-ProMyoFc (12) and pDP8 (46) plasmids, at a molar ratio of
1:1 in HEK293T cells. After 72 h incubation, cells were lysed, and
particles were purified by using iodixanol (Sigma-Aldrich) step-
gradient ultracentrifugation. The number of vector genomes was
determined relative to a plasmid DNA standard using dot-blot hybrid-
ization.
Animals. Male Wistar rats were obtained from Charles River
(Margate, UK). Animals were maintained at 22  0.5°C under a
12:12-h day-night cycle, were fed a standard maintenance chow diet
(Special Diet Services, LBS Biotechnology, Horley, Surrey, UK) ad
libitum, and acclimatized to their new surroundings for 1 wk. Subse-
quently, under brief isofluorane anesthesia, 7  1011 vector ge-
nomes of ProMyoAAV were injected percutaneously in 2  125 l
sterile saline in the right tibialis cranialis (TC) and extensor digitorum
longus (EDL) muscles of 150-g rats, with equivalent volumes of
saline being injected in the contralateral muscle group as control.
Seventeen days later, rats were starved overnight, and insulin-
stimulated glucose clearance in paired muscles was measured using
an intraperitoneal glucose tolerance test (IPGTT), combined with
administration of 2-[1,2-3H(N)]-deoxy-D-glucose (Perkin-Elmer;
Seer Green, Bucks, UK) tracer (11). Approximately 5 MBq were
administered per rat in 50% glucose/0.9% saline at 2 g/kg body wt.
Blood was collected by tail nick at 0, 15, 30, 60, and 90 min
postinjection, and blood glucose was measured immediately using an
Accu-Check Advantage meter (Roche Diagnostics, Burgess Hill,
West Sussex, UK). At the end of the IPGTT, rats were killed by
injection of pentobarbitone and their muscles rapidly dissected and
weighed. Portions of each TC muscle were mounted in OCT com-
pound (Sakura Finetech, Alphen aan den Rijn, Netherlands) and
frozen in liquid nitrogen-cooled isopentane or freeze-clamped and
stored at 80°C.
All experimental procedures were approved by the Royal Veteri-
nary College’s Ethics committee and were carried out under United
Kingdom Home Office license to comply with the Animals (Scientific
Procedures) Act 1986.
Glucose clearance into muscle. Fresh plasma was deproteinized, its
radioactivity was determined for each time point by liquid scintillation
counting in Ultima Gold XR (Perkin-Elmer) on an LS6500 Multipur-
pose scintillation counter (Beckman Coulter, High Wycombe, UK),
and the area under the curve (AUC) was calculated (Sigma Plot
version 11; Systat Software, Chicago, IL). Powdered muscle was
homogenized in water (Ultra-Turrax; IKA, Staufen, Germany), and
the phosphorylated deoxyglucose was separated in each homogenate
by passing through an anion exchange resin (Bio-Rad Laboratories,
Hemel Hempstead, UK) before -scintillation counting. The AUC
and the disintegrations per minute per unit mass of muscle were used
to calculate the clearance of deoxyglucose into each muscle. Plasma
insulin was determined using a Rat Insulin Radioimmunoassay kit
(Millipore). Triglyceride and glycogen were extracted from muscles
and quantified as previously described (41).
Determination of muscle fiber type distribution. Fiber type distri-
bution was determined by simultaneous immunostaining for myosin
heavy chain (MHC) isoforms type I, IIa, and IIb of 10-m cryosec-
tions. Transverse sections of TC muscles were air-dried and blocked
in 5% fetal calf serum (vol/vol) in phosphate-buffered saline contain-
ing 0.05% Triton X-100. MHC type I, IIa, and IIb fibers were
identified using A4.840 IgM, A4.74 IgG, and BF-F3 IgM antibodies,
respectively (Developmental Studies Hybridoma Bank, University of
Iowa), in sections also immunostained with anti-laminin antibody (no.
L9393, 1:100; Sigma). Type IIX fibers were identified by lack of
immunostaining using these MHC antibodies. Primary antibodies
were visualized using Alexa Fluor 488 (A11029, 1:200; Molecular
Probes, Invitrogen, Paisley, UK) and Alexa Fluor 633 (Molecular
Probes A21046, 1:200) secondary antibodies.
Muscle lysates, SDS-PAGE, immunoblotting. Protein expression
and phosphorylation of molecules present in muscle were assessed by
SDS-PAGE and quantification of Western blots, typically in dupli-
cate. Whole muscle lysates were prepared as previously described
(41). A crude membrane preparation was used for determination of
glucose transporter proteins, derived by homogenization using 20 mm
HEPES, pH 7.4, 1 mm EDTA, and 250 mm sucrose, containing 25
g/ml leupeptin, 10 g/ml aprotinin, 2 mmol/l sodium orthovanadate,
10 mmol/l NaF, 2.5 mM sodium pyrophosphate, and 1 mmol/l
polymethylsulfonyl fluoride (HES buffer) in a Dounce homogenizer,
followed by 700 g 4°C centrifugation for 10 min, centrifugation of the
supernatant at 100,000 g for 70 min at 4°C, and resuspension of the
pellet in HES buffer plus protease/phosphatase inhibitors and 2%
sodium dodecyl sulfate.
Protein content of lysate supernatants or membrane fractions was
quantified using the bicinchoninic acid method (Pierce Biotechnology,
Rockford, IL) using a BSA standard, normalized to the lowest con-
centration and denatured in Laemmli buffer for 10 min at 65°C.
Aliquots containing 15–80 g protein were resolved by SDS-PAGE,
electrotransferred, and immunoblotted as previously described (10).
Specific bands were detected using chemoluminescence (Western
Lightning Plus; Perkin Elmer) on Fuji Super RX film (Bedford, UK),
scanned and quantified using Image J software (NIH, Bethesda, MD).
Data for specific protein/phosphoprotein content of whole muscle
lysates were normalized to the geometric mean of the protein levels of
-actin, desmin, and glyceraldehyde 3-phosphate dehydrogenase in
each lysate and then to the mean of the control muscle values.
Real-time PCR assay. TC muscles were powdered under liquid
nitrogen and homogenized using an Ultra-Turrax (IKA) in Trizol
(Invitrogen). Extracted total RNA concentration and purity were
assessed using a Nanodrop 1000 (Wilmington, DE), and integrity was
confirmed by agarose gel electrophoresis. cDNA was generated using
an Omniscript kit (Qiagen, Crawley, UK) after genomic DNA diges-
tion. Real-time PCR analysis was performed using Fast Start SYBR
Green Reagent (Roche Diagnostics) on a Chromo4 detector (Bio-
Rad), with normalization to ROX fluorescence. Reaction mixtures
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contained 20 ng of cDNA and 1.5 M each primer and were subjected
to a 10-min hot start, followed by 40 cycles of 15 s at 95°C, 30 s at
55–58°C, and 30 s at 72°C, with a final 5 min extension. Primer pairs
(Invitrogen) were designed using Primer 3 (http://biotools.umassmed.edu/
bioapps/primer3_www.cgi) and are listed, together with the optimized
PCR conditions for each, as Table 1. The relative abundance of
cDNAs was quantified as previously described (43). Results are
quoted after normalization to the geometric mean of mRNA levels of
cyclophilin, 18S, and 36B4 expression for each muscle. Generation of
appropriate products was confirmed by melting curve analysis and
agarose gel electrophoresis.
Statistics. Data are quoted as means  SE. Comparisons between
treated and control muscles in the same animal were made using
Student’s paired t-test. Analyses were conducted using Sigma Plot
version 11, with P 	 0.05 regarded as significant.
RESULTS
Local overexpression of ProMyo results in localized muscu-
lar hypertrophy but no change in muscle fiber type distribution.
After injection of ProMyoAAV (17 days), ProMyo mRNA
was markedly increased in test vs. paired control muscles
(by 23-fold, P 	 0.001; Fig. 1A), consistent with a large
expected reduction in the availability of the mature peptide
(28). This resulted in the expected increase in expression of
mighty/akirin-1, a downstream mediator of myostatin action
(Fig. 1B) (31), and highly consistent increases in mass of
both test TC and EDL muscles over control muscles (by a
mean of 6.9 and 10.5%, respectively; both P 	 0.001; Fig. 2A),
despite the relatively short period that had elapsed since the
treatment. No effect of ProMyo overexpression was ob-
served on muscle fiber type distribution (percentage of type
I, IIA, IIB, and IIX fibers per transverse section; Fig. 2,
B–F) at this time point.
Local overexpression of ProMyo results in an elevation in
glucose disposal above that expected purely as a result of the
increased muscle mass. To establish whether myostatin in-
hibition altered acute glucose disposal, rats were subjected
to an IPGTT, combined with administration of radiolabeled
2-deoxyglucose to track glucose disposal. This resulted in a
typical IPGTT plasma glucose curve and an increase in
plasma insulin from a basal level of 121  36 to 348  53
pmol/l 30 min after intraperitoneal glucose administration,
consistent with the expected effect of a glucose load to
cause increased insulin secretion. Clearance of deoxyglu-
cose into test TC and EDL muscles was increased by 26 and
47%, respectively (P 
 0.020 and 0.024; Fig. 3A), during
the IPGTT, whereas glycogen synthesis was also increased
during this period (by 55% in TCs, P 
 0.002; not signif-
icant in EDLs; Fig. 3B), as demonstrated by increased
Table 1. Primer pair sequences and annealing temperatures for real-time PCR assays of skeletal muscle mRNA
expression levels
mRNA Target Accession No. Forward Primer Reverse Primer Annealing Temperature, °C
Cyclophilin NM_017101.1 CTGGCATCTTGTCCATGG GCTCCATGGCTTCCACAA 58
18S NR_046237.1 GGAGAGGGAGCCTGAGAAAC CAATTACAGGGCCTCGAAAG 55
36B4 NM_007475.5 CGACCTGGAAGTCCAACTAC ATCTGCTGCATCTGCTTG 55
IGF-I NM_001082477.2 CGGAGCTGTGATCTGAGGA GTCTTGGGCATGTCAGTGTG 55
IGF-I Rec NM_010513.2 TGACATCCGCAACGACTATC TTGGAGATGAGCAGGATGTG 58
FOXO3 NM_019740.2 CCATGGACAACAGCAACAAG TGGCGTTGGAATTGGTG 58
PGC1 NM_031347.1 ACAGCTTTCTGGGTGGATTG CGCTAGCAAGTTTGCCTCAT 55
p65 NM_199267.2 ATGCTGATGGAGTACCCTGA GAGAAGTCCATGTCCGCAAT 55
Activin IIBR NM_007397.2 CTACGACAGGCAGGAGTGTG TGGCTCGTACGTGACTTCTG 55
LTBP3 NM_008520.2 AACTGCTATCCTGGCTACCG TTTTCACATTTGCCATCAGG 55
MURF1 NM_080903.1 AGTGTGCCAACGACATCTTC CCGGTCCATGATCACTTCAT 55
Atrogin1 NM_133521.1 GACTTCTCGACTGCCATCCT TGAAGTTCTTTTGGGCGATG 55
Myostatin Propeptide NM_010834.2 GGCACTGGTATTTGGCAGAG GTCCTGGGAAGGTTACAGCA 55
Mighty NM_001030054.1 GAAAGCCAATTCTCCCTCCTC CCCACTTGTCGAAGGGTAAA 55
IGF-I, insulin-like growth factor-I; IGF-I Rec, IGF-I receptor; FOXO3, forkhead box O3; PGC1a, peroxisome proliferator-activated receptor coactivator 1;
p65, nuclear factor-B p65 subunit; activin IIBR, activin IIB receptor; LTBP3, latent transforming growth factor--binding protein; MURF1, muscle ring finger
protein 1.
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Fig. 1. Local injection of adeno-associated virus
(AAV)-8-myostatin propeptide (ProMyoAAV) in-
creases expression of muscle myostatin propeptide
(ProMyo) and akirin-1. After injection of AAV ex-
pressing ProMyo (17 days), ProMyo (A) and akirin-
1/mighty mRNA (B), measured using real-time PCR,
were increased in test vs. control tibialis cranialis
(TC) muscles. Data are means  SE (n 
 5–12).
Paired t-testing: *P 	 0.01 and ***P 	 0.001 vs.
control.
E816 LOCAL MYOSTATIN INHIBITION INCREASES MUSCLE GLUCOSE DISPOSAL
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00586.2013 • www.ajpendo.org
Downloaded from www.physiology.org/journal/ajpendo by ${individualUser.givenNames} ${individualUser.surname} (195.195.217.051) on September 17, 2018.
Copyright © 2014 American Physiological Society. All rights reserved.
incorporation of the radioactive tracer in the glycogen
molecule. In addition to this acute effect on glucose dis-
posal, ProMyo overexpression also resulted in increased
glycogen content of the muscles (by 28% in TCs, P 
 0.008
and by 41% in EDLs, P 
 0.007; Fig. 3C), likely reflecting
a sustained effect over the full period of the experiment.
Because these measurements are all expressed per unit mass
of muscle and muscle mass was also increased, it is clear that
the total glucose disposal by the treated muscles was markedly
enhanced by the treatment. For example, a simple extrapolation
from these findings would suggest that the mean total increase
in glucose uptake (increase in muscle mass multiplied by
increase in glucose uptake per unit mass) by test TCs and EDLs
would be 35 and 62%, respectively.
Triglyceride content and incorporation of radiolabel into
triglycerides during the IPGTT were also compared in test and
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Fig. 2. Reduced local myostatin peptide results in specific muscle hypertrophy. A: 17 days posttreatment there were increases in mass of both test TC and extensor
digitorum longus (EDL) muscles vs. paired controls (n 
 12). However, no differences in muscle fiber type distribution were identified in transverse TC muscle
sections by immunostaining for myosin heavy chain isoforms. B: summary of percentage fiber type composition (n 
 5; brown, type I; orange, type IIA; olive,
type IIB; green, type IIX). Representative photomicrographs from control muscle (C) and ProMyoAAV-treated muscle (D) immunostained green for laminin and
red for type I fibers and control muscle (E) and ProMyoAAV-treated muscle (F) immunostained green for type IIA and red for type IIB fibers. Filled bars, control;
open bars, test muscle. Data are means  SE. Paired t-testing: ***P 	 0.001 vs. control.
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control EDL muscles, but there were no effects of Pro-
MyoAAV injection (data not shown).
Increased glucose disposal is associated with increases in
glucose transporters. To establish whether the increase in
glucose disposal caused by ProMyoAAV administration might
occur secondary to effects on glucose transporter number, we
measured protein levels of GLUT1 and GLUT4 in membrane-
enriched lysate fractions from paired muscles. Although levels
of a membrane marker protein, caveolin-1, were unchanged by
the manipulation, both GLUT1 and especially GLUT4 were
increased in test muscles, by 19 and 63%, respectively (P 

0.031 and 0.043; Fig. 4). These data are consistent with
increased capacity for basal and especially insulin-stimulated
glucose uptake into propeptide-overexpressing muscles, which
likely mediates the observed effect on glucose disposal.
Increased glucose disposal occurs despite a modest reduc-
tion in activation of the PI3K signaling pathway. Translocation
of GLUT4 to the plasma membrane from its intracellular depot
is required for insulin-stimulated glucose uptake by muscle
cells, involving inhibition of the GTPase activity of the Rab-
GTPase-activating protein Akt substrate of 160 kDa (AS160/
TBC1D4) (7), whereas GSK3-mediated disinhibition of gly-
cogen synthase is necessary for glycogen synthesis. Both of
these events rely on activation of the PI3K/Akt signaling
pathway and activation of the serine/threonine kinase Akt.
Thus, to establish whether activation of the PI3K/Akt pathway
was also integral to the ProMyoAAV-induced increase in
muscle glucose disposal, we analyzed phosphorylation and
total protein levels of key signaling intermediates in muscle
lysates by Western blotting. Although phosphorylation of IRS1
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at Y608 was unchanged by the manipulation (Fig. 5A), phos-
phorylation of Akt at S473 was in fact decreased (by 33%, P

0.022; Fig. 5B), indicative of reduced kinase activity. This
unexpected reduction was accompanied by modest but consis-
tent reductions in phosphorylation at target residues of all four
of the Akt substrates assessed. AS160 phosphorylation was
reduced by 29% at T642 (P	 0.001; Fig. 5C), which would be
consistent with increased retention of GLUT4-carrying vesi-
cles intracellularly. Similarly, phosphorylation of GSK3 and
- was also reduced (by 21 and 17%, P 
 0.006 and 0.031;
Fig. 5, D and E), which would be expected to impair glycogen
synthase activation. In addition, S256 phosphorylation of fork-
head box protein O1 (FoxO1) was also reduced (by 23%, P 	
0.001; Fig. 5F), suggesting increased nuclear localization of
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Fig. 5. Increased glucose disposal occurs despite a modest reduction in activation of the phosphoinositol 3-kinase (PI3-kinase) signaling pathway. Paired TC
muscle lysates were generated in RIPA buffer and used in Western immunoblotting for phosphorylated and total PI3-kinase signaling intermediates. Effects of
myostatin silencing on phosphorylation of insulin receptor substrate 1 (IRS1, pY608) (A), protein kinase B (Akt, pS473) (B), Akt substrate of 160 kDa (AS160,
pT642) (C), glycogen synthase kinase (GSK) 3 (pS21) (D), GSK3 (pS9) (E), and forkhead box O (FOXO) 1 (pS256) (F) normalized to the geometric mean
of 3 housekeeping proteins [-actin, desmin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)] and to the contralateral control muscle. Phosphorylation
of all of these proteins except IRS1 was increased by the manipulation, whereas total levels of proteins of interest and housekeeping proteins were unchanged.
G: typical immunoblots for each protein/phosphoprotein are shown for ProMyo-treated and control muscles. *P	 0.05, **P	 0.01, and ***P	 0.001 vs. paired
control. Data are means  SE (n 
 11–12).
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this transcription factor. Total protein levels of all of the
signaling intermediates were not altered by the manipulation.
Thus, ProMyo overexpression results in reduced flux through
the PI3K/Akt pathway distal to IRS1, which would not explain
the observed effects on glucose disposal, but may instead be a
secondary effect of another consequence of myostatin inhibi-
tion.
Local myostatin inhibition causes a reduction in activation
of the AMPK signaling pathway in skeletal muscle. Because
activation of the AMPK pathway provides an alternative stim-
ulus for increased glucose disposal and AMPK phosphoryla-
tion and expression were reduced in myostatin null mice
(58), we assessed activating phosphorylation of AMPK at
T172 and phosphorylation of its substrate acetyl-CoA car-
boxylase (ACC) at the AMPK target residue S79. However,
again, we found that phosphorylation of both enzymes was
reduced by myostatin inhibition (AMPK by 35%, P 
 0.003,
Fig. 6A; ACC by 24%, P 	 0.001, Fig. 6B). Although total
AMPK protein was unaffected, these reductions in phosphor-
ylation were also accompanied by a mean 13% reduction in
ACC total protein (P
 0.009; Fig. 6C). Thus, our data rule out
AMPK activation as an explanation for the ProMyo-induced
increase in glucose disposal we have observed.
Myostatin blockade is associated with reduced expression of
selected mediators of muscle size and metabolism. In a further
attempt to explain the ProMyo-induced phenotype of increased
muscle mass and glucose disposal, we analyzed mRNA ex-
pression of a number of mediators having an impact on these
parameters by real-time PCR (shown in Fig. 7). Expression of
ActRIIB, the receptor for myostatin, was unchanged, but there
was a 9% reduction in latent TGF--binding protein 3
(LTBP3) expression (P 
 0.013), which is the most common
LTBP expressed in skeletal muscle and is thought to sequester
promyostatin extracellularly (4), implying that reduced tran-
scription is likely a compensatory effect of the overexpression.
Expression of the proatrophic transcription factor nuclear
factor-B (active p65 subunit) was unchanged, but there was a
small reduction in the expression of FoxO3 (11%, P 
 0.045).
Nevertheless, consistent with previous reports that myostatin
does not work through promotion of protein degradative/
atrophic pathways (50), expression of the E3 ubiquitin ligases
muscle ring finger protein (MURF) 1 and atrogin 1 (muscle
atrophy F-box protein) (5) were not altered.
With regard to prohypertrophic factors, there was no change
in expression of the mitochondrial regulator peroxisome pro-
liferator-activated receptor coactivator-1. Although IGF-I re-
ceptor (IGF-IR) mRNA was not significantly altered, there was
a small decrease in IGF-I expression (by 8%, P
 0.025), again
presumably a compensatory change for profound myostatin
inhibition. However, a local reduction in IGF-I may provide
the explanation for the observed reductions in activation of the
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SYBR Green Real-time PCR was conducted using 20 ng of each cDNA or
DNA standard in duplicate and primers as listed in MATERIALS AND METHODS.
Summary data (means  SE; n 
 10–12) are shown for each target mRNA of
interest [insulin-like growth factor-I (IGF-I), IGF-I receptor (IGF-I Rec),
FOXO3, peroxisome proliferator-activated receptor coactivator 1 (PGC1a),
nuclear factor-B p65 subunit (p65), activin IIB receptor (activin 2BR), latent
transforming growth factor--binding protein (LTBP3), muscle ring finger
protein 1 (MURF1), and atrogin 1], normalized to the geometric mean of the
reference mRNAs cyclophilin, 36B4, and 18S. Filled bars, control; open bars,
test muscle. *P 	 0.05 vs. paired control muscles for each target.
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PI3K/Akt and AMPK signaling pathways in ProMyoAAV-
injected muscles.
DISCUSSION
In our study we have demonstrated that local inhibition of
myostatin action in skeletal muscle for only a relatively short
period is capable of generating both increased muscle mass and
glucose disposal in rats. Both glucose uptake and glycogen
synthesis were increased when measured per unit muscle mass.
Thus, the combination of simultaneous increases in muscle
mass and glucose disposal would imply that there was a
marked increase in total glucose disposal in the muscle group
tested. The fact that this enhancement was present just 17 days
after injection of the virus suggests that, with additional time,
a greater magnitude of effect could be expected because of
further accretion of muscle tissue. We have also observed a
greater than proportional increase in glucose disposal both as a
result of acute muscle Akt-2 overexpression (11) and universal
overexpression of urocortin-3 (20), implying the possibility of
a more general mechanism worthy of deeper investigation.
The increased glucose disposal was associated with in-
creased GLUT1 and GLUT4 glucose transporter content, im-
plying an increased capacity for both basal and insulin-stimu-
lated glucose uptake (the latter being of more relevance during
the IPGTT, when total levels of plasma membrane GLUT4
would be much higher than those of GLUT1). The results of
transgenic overexpression of GLUT4 in muscle (51) suggest
that this change would be sufficient to explain the improved
glucose disposal observed here, and indeed both basal and
insulin-stimulated glucose disposal and GLUT4 protein were
elevated in an analogous in vivo model of deficient myostatin
action, the myostatin null mouse (58), while muscle glycogen
content was also increased by treatment with an ActRIIB
inhibitor (14). We can speculate that the increased glycogen
synthesis is likely a result of allosteric stimulation of glycogen
synthase activity by rising levels of glucose 6-phosphate,
secondary to increased glucose transport, since we found
GSK3 phosphorylation at Ser9 to be reduced. Furthermore,
because no differences in triglyceride synthesis or content were
noted in propeptide-overexpressing muscles, it does not appear
that the effects on glucose disposal are secondary to reduced
lipid accumulation, although we do not have data regarding
some of the more bioactive lipid species.
At first glance, the modest downregulation of the AMPK and
PI3K/Akt signaling pathways in the ProMyo-treated muscles
seems to be counterintuitive, since these pathways mediate
both muscle hypertrophy and glucose disposal. Akt has the
potential to regulate muscle size through several mechanisms,
including via phosphorylation of both GSK3 and FoxOs.
GSK3 inhibits the translation initiation factor eIF2B (44),
whereas FoxOs have been shown to promote muscle atrophy
through activation of the E3 ubiquitin ligases MURF1 and
atrogin-1 (45, 48). In a previous study, myostatin overexpres-
sion in rats did not alter levels of expression or phosphorylation
of FoxO1, or indeed expression of E3 ubiquitin ligases (3).
Instead, this manipulation caused inhibition of the Akt-mTOR
pathway, suggesting an impact on protein synthesis rather than
degradation, an effect that was borne out here by the lack of
effect of ProMyoAAV injection on MURF1 and atrogin-1.
However, transgenic overexpression of FoxO1 in mouse skel-
etal muscle caused atrophy (21); thus, the reduction in FoxO1
phosphorylation would tend to support the hypertrophy in-
duced by myostatin blockade in our study. Both FoxO1 (8) and
FoxO3 (15) and their target genes have been shown to be
regulated by AMPK as well as Akt; thus, the reduced phos-
phorylation/expression of these transcription factors may be
secondary to reduced activation of either upstream kinase.
The observed reduction in IGF-I expression in the test
muscles may at least in part explain the reduced activation of
the PI3K/Akt pathway, of which it is a key activator, and also
the AMPK pathway (38). This change is consistent with that
observed previously in myostatin knockout mice (13, 55),
although in these animals the reduction in IGF-I was accom-
panied by increases in IGF-IR and IGF-I-binding protein ex-
pression and/or increased IGF-II expression. Muscle-derived
IGF-I is known to have important paracrine/autocrine effects
(20, 42); thus, a local compensatory effect of myostatin inhi-
bition to decrease IGF-I mRNA transcription may be impli-
cated here. Although we did not detect a change in phosphor-
ylation of IRS1, the usual adaptor protein recruited by the
IGF-IR to activate the PI3K/Akt pathway (42), it is possible
that this was a sensitivity artifact of the Western blot or that an
alternative adaptor protein may have been recruited, for exam-
ple, IRS2 (49). Although many publications have investigated
the effects of myostatin inhibition downstream at the level of
Akt and below, there is little published information on the
impact of this manipulation upstream of Akt.
Injection of ProMyoAAV in a specific muscle group resulted
in local effects, since a number of significant differences in
muscle mass, metabolism, and signaling were demonstrated in
the injected muscles. In addition, our data confirm that in-
creased muscle mass alone is not the likely explanation for the
observed beneficial effects of systemic myostatin inhibition
on metabolism, which include reduced fat mass, increased
“browning” of adipose tissue, and improved whole body insu-
lin sensitivity (1, 16, 17, 34, 58–60). These effects make
systemic inhibition of myostatin a potentially viable approach
for the therapy of T2D, the metabolic syndrome, and sar-
copenic obesity. A number of approaches aimed at reducing
myostatin action for the treatment of muscular dystrophies
have already been considered, including gene therapy by de-
livery of myostatin-inhibiting genes, propeptide or small-inter-
fering RNA using AAV or retrovirus (12, 18, 57), administra-
tion of antimyostatin blocking antibodies (52) or ActRIIB
competitors (1, 14, 36, 59), and antisense oligonucleotide-
mediated exon skipping (22, 23). However, it is unclear as yet
whether any of these therapeutic modalities will have long-
term potential for the treatment of metabolic disorders, and
thus more research into mechanisms and applications is war-
ranted.
In conclusion, our study demonstrates that myostatin inhi-
bition has autocrine/paracrine effects to enhance glucose up-
take and glycogen synthesis in skeletal muscle of rats, which
are likely mediated through increased membrane levels of
GLUT1 and GLUT4 glucose transporters. This effect occurs in
tandem with increased muscle mass, but is additional to it, thus
magnifying the overall effect. These findings support the po-
tential utility of strategies aimed at inhibiting skeletal muscle
myostatin action in the treatment of metabolic disorders, in-
cluding T2D and sarcopenic obesity.
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